Status:
TERMINATED
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
Lead Sponsor:
Sanofi
Conditions:
Hyperuricemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previo...
Eligibility Criteria
Inclusion
- Patients with histologically proven aggressive Non Hodgkin's Lymphoma
Exclusion
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00664144
Start Date
July 1 2002
End Date
January 1 2005
Last Update
March 7 2012
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Diegem, Belgium
2
Sanofi- Aventis Administrative Office
Paris, France
3
Sanofi-Aventis Administrative Office
Berlin, Germany
4
Sanofi-Aventis Administrative Office
Milan, Italy